Pick and mix approach works well for coronavirus vaccines

29 June 2021
2019_vials_lab_biotech_research_big

Results from  a study evaluating the impact of mixing different coronavirus vaccines has found that all tested combinations produced a potent immune response among participants.

With funding from the British government, the Oxford Vaccine Group has been running the Com-Cov vaccine trial to determine the degree of flexibility doctors may have in prescribing different vaccines.

Researchers looked at the efficacy of either two doses of BNT162b2/Comirnaty, from Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX), two of Vaxzevria, from AstraZeneca (LSE: AZN), or one followed by the other.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology